Overview
Antiverse, a Cardiff-based biotech company, has raised £7 million in a Series A funding round led by Soulmates Ventures, with participation from several investors. This funding will help scale its AI-designed therapeutic antibody platform aimed at undruggable disease targets, particularly in cystic fibrosis research. Antiverse has partnered with the Cystic Fibrosis Foundation to develop novel antibodies targeting the CFTR protein, and aims to advance its internal drug pipeline and clinical testing by 2027.
Products
Loading...
Recent Deals
Investors: Soulmates Ventures
Antiverse, a Cardiff-based biotech company, has raised £7 million in a Series A funding round led by Soulmates Ventures, with participation from several investors. This funding will help scale its AI-designed therapeutic antibody platform aimed at undruggable disease targets, particularly in cystic fibrosis research. Antiverse has partnered with the Cystic Fibrosis Foundation to develop novel antibodies targeting the CFTR protein, and aims to advance its internal drug pipeline and clinical testing by 2027.